International Journal of Cardiology
Volume 152, Issue 3 , Pages 327-331 , 3 November 2011

Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction — A nationwide study

  • C.H. Jørgensen

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 — post 67, 2900 Hellerup, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 39 97 87 15, +45 26 81 05 03; fax: +45 70 20 12 81.
    • ,
  • G.H. Gislason

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 — post 67, 2900 Hellerup, Denmark
    • ,
  • D. Bretler

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 — post 67, 2900 Hellerup, Denmark
    • ,
  • R. Sørensen

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 — post 67, 2900 Hellerup, Denmark
    • ,
  • M.L. Norgaard

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 — post 67, 2900 Hellerup, Denmark
    • ,
  • M.L. Hansen

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 — post 67, 2900 Hellerup, Denmark
    • ,
  • T.K. Schramm

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 — post 67, 2900 Hellerup, Denmark
    • ,
  • S.Z. Abildstrom

      Affiliations

    • Cardiovascular Research Unit, Department of Internal Medicine, Copenhagen University Hospital Glostrup, Glostrup, Denmark
    • National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark
    • ,
  • C. Torp-Pedersen

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 — post 67, 2900 Hellerup, Denmark
    • ,
  • P.R. Hansen

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 — post 67, 2900 Hellerup, Denmark

Received 14 November 2009 ,Revised 5 May 2010 ,Accepted 16 July 2010.

References 

  1. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation. 2008;117:296–329
  2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–2581
  3. O'Rourke B. Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res. 2004;94:420–432
  4. Gribble F, Tucker S, Seino S, Ashcroft F. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes. 1998;47:1412–1418
  5. Hausenloy DJ, Yellon DM. Protecting the myocardium at time of reperfusion–meeting report of the Hatter Institute 4th International Workshop on Cardio-protection. Basic Res Cardiol. 2005;100:383–386
  6. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003;56:124–130
  7. Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM. Development and validation of the ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol. 2001;37:992–997
  8. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19:789–830[Suppl]
  9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853
  10. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49:930–936
  11. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diab Care. 2008;31:1672–1678
  12. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diab Care. 2002;25:2244–2248
  13. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113–1151
  14. Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab. 2003;29:207–222
  15. Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. Heart. 2004;90:9–12
  16. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 1999;20:439–446
  17. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103:3111–3116
  18. Kao J, Tobis J, McClelland RL, et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004;93:1347–1350, A1345.
  19. Bhamra GS, Hausenloy DJ, Davidson SM, et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol. 2008;103:274–284
  20. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999;33:119–124
  21. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733–742
  22. Lee T-M, Chou T-F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88:531–537
  23. Johnsen SP, Monster TB, Olsen ML, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006;13:134–140
  24. Danchin N, Charpentier G, Ledru F, et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev. 2005;21:143–149
  25. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007;59:418–458
  26. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009;131:149–150

PII: S0167-5273(10)00554-1

doi: 10.1016/j.ijcard.2010.07.027

International Journal of Cardiology
Volume 152, Issue 3 , Pages 327-331 , 3 November 2011

Article Tools

* Image Usage & Resolution